Loeliger E A, van der Hoeff-van Halem R, van Halem-Visser L P
Thromb Haemost. 1978 Oct 31;40(2):272-87.
Standardization of the thromboplastin most commonly used for anticoagulant control in The Netherlands has been achieved by the Dutch Reference Laboratory for Anticoagulant Control. The system established for control indicates the performance characteristics of each batch of thromboplastin in patients relative to a national calibration batch. Calibration constants were assessed according to an ICTH/ICSH proposal and with a reproducibility of approximately 2% (CV). With the use of a given calibration constant of the International Reference Preparation of Thromboplastin (1.0) and after assessment of the calibration constant of the National Reference Preparation in international terms (0.93), the accuracy of calibration with the various modifications of the calibration procedure is of the order of magnitude of 3% (CV). On the basis of the calibration protocol, physicians will be provided with correlation tables containing, for their convenience, prothrombin (thromboplastin) times in terms of the reference thromboplastin (uniform, i.e., batch-independent, prothrombin times), conventional prothrombin activity (percentages), and in due course with International Calibrated Ratios. With this approach current practice in the prescription of oral anticoagulants will be maintained. Opportunity is given, however, to aim at internationally proposed therapeutically optimal target values.
荷兰抗凝控制参考实验室已实现了荷兰最常用于抗凝控制的凝血活酶的标准化。所建立的控制体系表明了相对于国家校准批次，每一批凝血活酶在患者中的性能特征。校准常数是根据国际血栓与止血学会/国际血液学标准化委员会的提议进行评估的，其重现性约为2%（变异系数）。使用国际参考凝血活酶制剂的给定校准常数（1.0），并在国际范围内评估国家参考制剂的校准常数（0.93）之后，各种校准程序修改的校准准确度约为3%（变异系数）。根据校准方案，将为医生提供相关表格，为方便起见，表格中包含以参考凝血活酶表示的凝血酶原（凝血活酶）时间（统一的，即与批次无关的凝血酶原时间）、常规凝血酶原活性（百分比），并适时提供国际标准化比值。通过这种方法，口服抗凝剂处方的当前做法将得以维持。然而，有机会瞄准国际提议的治疗最佳目标值。
